Krystal Biotech stock hits 52-week low at $127.33

Krystal Biotech (KRYS) shares hit a 52-week low despite strong gross margins and cash reserves, following a Q1 2025 earnings miss with EPS at $1.20 versus $1.46 expected and revenue at $88.18 million versus $99.12 million expected. While net product revenue for VYJUVEC grew 95% year-over-year, a decrease in new patient start forms was observed; H.C. Wainwright maintains a Buy rating with a $240 price target, citing anticipated revenue shortfall due to seasonal insurance changes and upcoming VYJUVEC launches in Germany, France, and Japan.

Analysis

Krystal Biotech Inc. (KRYS) shares have reached a 52-week low of $127.33, reflecting a -24.28% decline over the past year, despite InvestingPro analysis suggesting the stock is undervalued and the company maintaining robust gross profit margins of 93.2%. The recent Q1 2025 earnings report revealed a miss on analyst expectations, with EPS at $1.20 against a forecasted $1.46, and revenue of $88.18 million compared to an anticipated $99.12 million. This shortfall occurred even as net product revenue for its flagship treatment, VYJUVEC, demonstrated significant year-over-year growth of 95%. The company's financial position remains strong, evidenced by $765.3 million in cash reserves, more cash than debt, and high liquidity ratios. H.C. Wainwright reiterated a Buy rating with a $240.00 price target, attributing the revenue miss to seasonal insurance changes, the impact of which was reportedly less severe than in the previous year. Krystal Biotech also noted a decrease in new patient start forms, potentially due to patients being more integrated or having milder forms of Dystrophic Epidermolysis Bullosa (DEB), prompting intensified sales and field activities. Future growth drivers include planned VYJUVEC launches in Germany, France, and Japan starting Q3 2025, and anticipated clinical trial readouts for cystic fibrosis and Alpha-1 Antitrypsin Deficiency lung disease by the end of 2025.

Key Decisions for Investors

• Investors should weigh the current stock price weakness and recent earnings miss against the company's strong underlying fundamentals, including high gross margins, a solid cash position, and significant year-over-year revenue growth for VYJUVEC.
• Monitor upcoming catalysts such as VYJUVEC's international launches in Q3 2025 and clinical pipeline readouts by year-end 2025, which could significantly impact future revenue streams and market perception.
• Evaluate the company's strategies to address the decrease in new patient start forms and assess the potential for undervaluation as suggested by InvestingPro, considering the H.C. Wainwright price target of $240.00.